XTL Biopharmaceuticals
XTLB
3 hedge funds and large institutions have $97K invested in XTL Biopharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.02% less ownership
Funds ownership: 0.02% → 0% (-0.02%)
40% less funds holding
Funds holding: 5 → 3 (-2)
83% less capital invested
Capital invested by funds: $579K → $97K (-$482K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$13.7K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$5.41K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$434K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$50K |
| 3 |
Invesco
Atlanta,
Georgia
|
-$11 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Invesco
Atlanta,
Georgia
| $68K | -$11 | -1 | -0% |
|
|
2
Morgan Stanley
New York
| $15K | +$13.7K | +1,220 | +718% |
|
|
3
UBS Group
Zurich,
Switzerland
| $14K | +$5.41K | +483 | +57% |
|
|
SM
4
Sabby Management
Miami Beach,
Florida
| – | -$434K | -36,207 | Closed |
|
|
5
Citadel Advisors
Miami,
Florida
| – | -$50K | -4,159 | Closed |
|
XTLB Hedge Fund Activity: Q1 2017 in Review
3 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q1 2017, worth a combined $97K — down 83% from $579K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of XTLB and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Morgan Stanley, adding an estimated $13.7K. The largest seller was Sabby Management, exiting entirely with an estimated $434K sold.
- 3 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q1 2017, down from 5 in Q4 2016.
- Funds reported $97K of XTL Biopharmaceuticals stock for Q1 2017, down 83% quarter-over-quarter.
- 0 funds opened new XTL Biopharmaceuticals positions in Q1 2017 and 2 closed out, a net change of -2 holders.
- The largest XTL Biopharmaceuticals buyer in Q1 2017 was Morgan Stanley, an estimated $13.7K added.
- The largest XTL Biopharmaceuticals seller in Q1 2017 was Sabby Management, an estimated $434K sold.
Based on aggregated 13F filings for Q1 2017.